Summary of Results
Endocrine, nutritional and metabolic
|Guidance:||Obesity - orlistat|
|Description:||The summary of the withdrawn technology appraisal on Obesity - orlistat. It links to the withdrawn guidance and key documents.|
NICE implementation uptake reports
|Implementation uptake report||Assessment||Published Date||Coverage|
Johnston A et al
A clinical audit to investigate the compliance of general practitioners to NICE guidelines for the prescribing of anti-obesity drugs sibutramine and orlistat.
International Journal of Pharmacy Practice
|Doubts about or mixed impact in practice||Local|
Cullum N, Dawson D, Lankshear A et al.
The Evaluation of the Dissemination, Implementation and Impact of NICE Guidance.
|Doubts about or mixed impact in practice||National|
Wathen B et al
An Evaluation of the Impact of NICE Guidance on GP Prescribing.
British Journal of General Practice
NICE guidance for anti-obesity medication: is it being followed?
Journal of Human Nutrition and Dietetics
|Practice appears not to be in line with guidance||National|
Sheldon T, Cullum N, Dawson D, Lankshear A, Lowson K, Watt I, West P, Wright D, & Wright J
What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews
British Medical Journal
This page was last updated: 28 August 2007